Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01030783 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma
A Phase 3 study, sponsored by AVEO Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 517
- Enrollment target
NCT01030783 is a Phase 3 study that has completed, run by AVEO Pharmaceuticals. The registered enrollment target is 517 participants.
The verdict
NCT01030783, a Phase 3 study, has completed, sponsored by AVEO Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 517 participants
- Enrollment target
Study Summary
This is an open-label, randomized, controlled, multi-national, multi-center, parallel-arm trial comparing tivozanib to sorafenib in subjects with advanced RCC. The study is designed to compare the PFS, OS, ORR, DR, safety and tolerability, and kidney specific symptoms/health outcome measurements of tivozanib and sorafenib.
Interventions
- DRUG Sorafenib
- DRUG tivozanib (AV-951)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 517 participants |
| Start Date | 2009-12 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01030783
The ClinicalTrials.gov registry entry for NCT01030783 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 517 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AVEO Pharmaceuticals, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT01030783 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01030783 about?
NCT01030783 is a clinical study titled "A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma". This is an open-label, randomized, controlled, multi-national, multi-center, parallel-arm trial comparing tivozanib to sorafenib in subjects with advanced RCC. The study is designed to compare the PFS, OS, ORR, DR, safety and tolerability, and kidney specific symptoms/health outcome measurements of ...
What is the current status of trial NCT01030783?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 517 participants. The study started on 2009-12. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01030783?
The interventions under investigation include: Sorafenib (DRUG), tivozanib (AV-951) (DRUG).
Who is sponsoring clinical trial NCT01030783?
This trial is sponsored by AVEO Pharmaceuticals, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.